Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $90.1 million versus the consensus estimate of $91.51 million.

“ACADIA entered 2020 with positive momentum. Successful execution of our commercial efforts led to continued strong performance of NUPLAZID® for Parkinson’s disease psychosis and our plans remain on track for delivering a potential second indication with pimavanserin for the treatment of DRP. We also continue to invest in our late-stage pipeline and business development opportunities to shape our mid and long-term growth strategy,” said Steve Davis, ACADIA’s Chief Executive Officer. “Our results this quarter reflect the dedication of our employees and I am proud of our team’s commitment to the patients we serve while adapting to the challenges of the global COVID-19 pandemic.”

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.